Patents Assigned to Pfizer
  • Crystalline form of lorlatinib free base
    Patent number: 10420749
    Abstract: This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 24, 2019
    Assignee: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa J. Birch
  • Cyclopentane-Based Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20190284216
    Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 11, 2019
    Publication date: September 19, 2019
    Applicant: Pfizer Inc.
    Inventors: Martin James Wythes, Indrawan James McAlpine, Ryan Patman, Eugene Yuanjin Rui, Andrew Fensome, Andreas Maderna, Mehran Jalaie, Ketan S. Gajiwala
  • Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
    Patent number: 10414748
    Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: September 17, 2019
    Assignee: Pfizer Inc.
    Inventor: Christopher Scott Seadeek
  • Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
    Publication number: 20190275049
    Abstract: This invention relates to a method of treating non-small cell lung cancer by administering an EGFR T790M inhibitor in combination with a CDK inhibitor to a patient in need thereof.
    Type: Application
    Filed: November 7, 2017
    Publication date: September 12, 2019
    Applicant: PFIZER INC.
    Inventors: Zelanna Iris GOLDBERG, Yuli WANG, Scott Lawrence WEINRICH, Keith David WILNER
  • 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
    Publication number: 20190276472
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Applicant: PFIZER INC.
    Inventors: MICHAEL AARON BRODNEY, CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, CHRISTOPHER JOHN HELAL, STEVEN VICTOR O'NEIL, PATRICK ROBERT VERHOEST
  • ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20190269791
    Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
    Type: Application
    Filed: October 3, 2017
    Publication date: September 5, 2019
    Applicant: Pfizer Inc.
    Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
  • Methods of Controlling Morphology of Polymeric Nanoparticles
    Publication number: 20190269617
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Application
    Filed: March 6, 2019
    Publication date: September 5, 2019
    Applicant: Pfizer Inc.
    Inventors: Donald Parsons, Mir Mukkaram Ali, Nicholas Jon Boylan
  • Cycloalkyl-Linked Diheterocycle Derivatives
    Publication number: 20190270737
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Application
    Filed: May 20, 2019
    Publication date: September 5, 2019
    Applicant: Pfizer Inc.
    Inventors: Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Robert Louis Hoffman, Peter Qinhua Huang, Robert Steven Kania, Pei-Pei Kung, Maria Angelica Linton, Lakshmi Sourirajan Narasimhan, Paul Francis Richardson, Daniel Tyler Richter, Graham Smith
  • Cyclic Peptides As C5a Receptor Antagonists
    Publication number: 20190270778
    Abstract: The invention relates to cyclic peptide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to cyclic peptide C5a receptor antagonists of formula (Ia) or formula (Ib), or pharmaceutically acceptable salts thereof, wherein R1a, R1b, R2, R3 and R4 areas defined in the description. C5a receptor antagonists are potentially useful in the treatment of a wide range of 1 disorders, including inflammatory disorders and immune disorders.
    Type: Application
    Filed: July 17, 2017
    Publication date: September 5, 2019
    Applicant: Pfizer Inc.
    Inventors: Ye Che, Yiqing Feng, Matthew Merrill Hayward, David Hepworth, Peter Jones, Kaila Neelu, Nikolaos Papaioannou
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20190270751
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors
    Publication number: 20190263816
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
    Type: Application
    Filed: June 9, 2016
    Publication date: August 29, 2019
    Applicant: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
  • IL-15 Variants and Uses Thereof
    Publication number: 20190263877
    Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 29, 2019
    Applicant: Pfizer Inc.
    Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
  • Bifunctional cytotoxic agents
    Patent number: 10391182
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • Glycoconjugation process
    Patent number: 10392420
    Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: August 27, 2019
    Assignee: Pfizer Inc.
    Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
  • Bispecific antibodies
    Patent number: 10392438
    Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: August 27, 2019
    Assignee: PFIZER INC.
    Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
  • Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
    Patent number: 10385036
    Abstract: The present invention provides sulfonamide-substituted indoles and Methods of Use Thereof-substituted pyrrolopyridines, pharmaceutical compositions thereof methods of modulating RORy activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: August 20, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand J. Unwalla
  • Tetrahydroquinazoline Derivatives Useful as Anticancer Agents
    Publication number: 20190248767
    Abstract: Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 15, 2019
    Applicant: PFIZER INC.
    Inventors: Simon PLANKEN, Hengmiao CHENG, Michael Raymond COLLINS, Jillian Elyse SPANGLER, Alexei BROOUN, Andreas MADERNA, Cynthia PALMER, Maria Angelica LINTON, Asako NAGATA, Ping CHEN
  • Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
    Patent number: 10376531
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 13, 2019
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH
    Publication number: 20190240226
    Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 9, 2017
    Publication date: August 8, 2019
    Applicant: Pfizer Inc.
    Inventor: Steven Martin Evans
  • Process for the preparation of fluticasone propionate form 1
    Patent number: 10370402
    Abstract: The invention relates to a novel crystallization process for preparing fluticasone propionate as crystalline form 1 polymorph with controlled particle size and suitable for micronization. Said process comprises the step of dissolving fluticasone propionate in acetone or in a mixture of acetone and water and then adding this solution to water or to a mixture of water 10 and acetone, thereby causing fluticasone propionate to crystallize out of the solution as crystalline form.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: August 6, 2019
    Assignee: Pfizer Limited
    Inventors: Martyn David Ticehurst, Ivan Marziano, Eleftherios Kougoulos